Angelman Syndrome

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

Long-term Extension of GTX-102 in Angelman Syndrome

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

Parent and Infant Inter(X)Action Intervention (PIXI)

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)

Early Check: Expanded Screening in Newborns

A Natural History Study of Angelman Syndrome

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman Syndrome

Italian Angelman Syndrome Registry

IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)

Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome

A Study in Adults and Adolescents With Angelman Syndrome (STARS)

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome